ALGS: Pevifoscorvir and a novel ASO program aim to expand HBV functional cure rates through innovative mechanisms
The session highlighted novel HBV therapies addressing unmet needs beyond current nucleoside analogues and ASOs. Pevifoscorvir targets multiple HBV life cycle steps and shows promise in ongoing phase II trials, while a new ASO program and combination strategies aim to expand functional cure rates.B…